In this report, updated guidelines for the evaluation, medical, and surgical management of prostate cancer are presented. They are categorized according the stage of the disease using the tumor node metastasis staging system 7 th edition. The recommendations are presented with supporting evidence level.
Guidelines

MANUSCRIPT
In Saudi Arabia, prostate cancer is the 6 th most common cancer among men of all ages and the most common cancer among men over the age of 75. It accounts for 6.1% of all newly diagnosed cases among males in year 2010 with an age-standardized incidence rate of 5.5/100,000 among the male population. Stage at the time of diagnosis is localized in 43.9% of cases with the remainder being either locally advanced, metastatic or unknown. [1] 1. STAGING EVALUATION Once diagnosis is confirmed, the following staging evaluation should be done:
1.1. Computed tomography (CT) or magnetic resonance imaging (MRI) abdomen and pelvis: Should only be done when the cancer is considered high-risk [ Table 1 ] (EL-2). [ MANAGEMENT OPTIONS This will depend on the stage (localized vs. metastatic), the risk group and life expectancy. [7] 3.1. Localized disease (cT1-cT2) 3.1.1. Low risk: Options of therapy depend on the following factors: 3.1.1.1. If the patient is asymptomatic with life expectancy <5 years: No further intervention required until he becomes symptomatic or clinical progression [8] [9] [10] (EL-2). 3.1.1.2. If asymptomatic with life expectancy between 5 and 10 years: Active surveillance (involves active monitoring of the course of disease with the expectation to intervene with curative intent if the cancer progresses) [8] [9] [10] (EL-2). 3.1.1.3. If asymptomatic with life expectancy >10 years: Options include active surveillance, [10] radical prostatectomy (RP), [11] external beam radiation therapy (EBRT), [12] or brachytherapy [13] (EL-2 or progression in any of the aforementioned criteria. [14, 15] 3.1.1.6. All RPs should be done in tertiary care centers by high-volume surgeons [16] (EL-2). 3.1.1.7. Lymphadenectomy can be omitted if the chance of being positive is <5% [17] (EL-2). 3.1.1.8. Intensity-modulated EBRT is the minimal standard of EBRT, in which the only acceptable biological dose is ≥74 Gy [12, [18] [19] [20] [21] [22] (EL-2). 3.1.2. Intermediate risk: Options of therapy depend on the following factors: 3.1.2.1. If life expectancy is < 5 years: Patient will have no further intervention until he becomes symptomatic or clinical progression [8] [9] [10] (EL-2). 3.1.2.2. If life expectancy is between 5 and 10 years: Options include active surveillance, [10] EBRT with 6 months of androgen deprivation therapy (ADT), [12, 20, 23] or RP [11] (EL-2). 3.1.2.3. If life expectancy is more than 10 years: Options are RP with extended lymphadenectomy [11, 24] (EL-1) or EBRT + 6 months of ADT [12, 18, 19, 23] (EL-2).
High-risk: Options include EBRT (to include
pelvic lymph nodes) with 18-36 months of ADT. [25] [26] [27] [28] [29] [30] [31] (EL-1) or RP with extended lymphadenectomy [32, 33] (EL-3). Patients who have advanced local disease and are unfit for the above mentioned two options may be given ADT alone (when PSA level exceeds 10 ng/mL) [34] (EL-1).
Follow-up after curative therapy: Patients
should have a disease-specific history, serum PSA and digital rectal examination at 3, 6, and 12 months after therapy, then every 6 months for 3 years and then annually [35] (EL-3 [36] [37] [38] [39] [40] (EL-2). 3.1.2.5. Patients who have positive (not focal) surgical margins may undergo adjuvant EBRT to the prostatic bed, [25, 26] or intensive expectant follow-up [41, 42] (EL-2). 3.1.5. Management of recurrence post RP: [53] [54] [55] Gleason > 7 , o r c l i n i c a l l y indicated (EL-2). 3.1.6. Management of local recurrence after EBRT 3.1.6.1. Definition: A PSA rise 2 ng/mL above the PSA nadir is the most reliable indication for recurrence [56, 57] (EL-2). However, local recurrence is defined by the presence of all of the following: [58, 59] A prostatic biopsy showing malignant cells 18 months or longer after EBRT, associated rise in PSA, and no evidence of distant metastasis documented by CT scan or MRI and bone scan.
Options of therapy include:
Observation up to PSA of 10 ng/dl, then ADT, [60] or in carefully selected patients, salvage prostatectomy, or brachytherapy may be considered. [ [65] [66] [67] (EL-1).
Options of ADT include:
Orchiectomy, luteinizing hormone releasing hor mone (LHRH) antagonist, LHRH agonists, and complete androgen blockade (CAB) continuous or intermittent. [65] [66] [67] m e t a s t a t i c C R P C t re a t m e n t o p t i o n s include abiraterone with prednisone, systemic c h e m o t h e r a py, o r secondary hormonal m a n i p u l a t i o n s (adding a nonsteroidal a n t i a n d r o g e n , o r a n t i a n d r o g e n withdrawal). [ [109] [110] [111] (EL-3). 3.2.2.2.9. Patients with bony m e t a s t a t i c C R P C s h o u l d r e c e i v e rank-ligand antibodies (Denosumab) therapy every 4 weeks (EL-1), but when not available zoledronic acid can be given (EL-1). [112] [113] [114] [115] [116] [117] 
